Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

BACKGROUND: Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their met...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xichun, Cao, Jun, Hu, Wenwei, Wu, Changping, Pan, Yueyin, Cai, Li, Tong, Zhongsheng, Wang, Shusen, Li, Jin, Wang, Zhonghua, Wang, Biyun, Chen, Xiaoyu, Yu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237755/
https://www.ncbi.nlm.nih.gov/pubmed/25376790
http://dx.doi.org/10.1186/1471-2407-14-820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237755/
https://www.ncbi.nlm.nih.gov/pubmed/25376790
http://dx.doi.org/10.1186/1471-2407-14-820

Ejemplares similares